Skip to content
Tech News
← Back to articles

AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

2026-07-08 | original
read original more articles

Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments.

Explore topics: astrazeneca astrazeneca eligible biopharmaceutical biopharmaceutical receive eligible
Related:
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
Incyte to Buy Vega Therapeutics For Up to $2 Billion
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results
AstraZeneca’s Imfinzi Gets Expanded EU Label With Approval for Gastric Cancer

© 2026 GoKawiil

About | Editorial Policy | Contact